Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

NCT00281021 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

26

Enrollment

OTHER

Sponsor class

Stopped Interim analysis revealed that only 1 patient had a partial response.

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

DRUG: Erlotinib plus Digoxin

Sponsor

University of Louisville

Collaborators

[object Object]